Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07649070 · ClinicalTrials.gov registry record · Phase 2

Phase 2 Trial of G207 + 5 Gy Radiation for Children With High-Grade Gliomas

A Phase 2 study, sponsored by M.D. Anderson Cancer Center.

Not yet
Registry status
Phase 2
Development phase
38
Enrollment target

NCT07649070: Clinical Trial Phase 2 study, sponsored by M.D. Anderson Cancer Center.

NCT07649070 is a Phase 2 study that has not yet begun recruiting, run by M.D. Anderson Cancer Center. The registered enrollment target is 38 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (71% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT07649070, a Phase 2 study, has not yet begun recruiting, sponsored by M.D. Anderson Cancer Center.

NOT YET RECRUITING
Registry status
Phase 2
Development phase
38 participants
Enrollment target

Study Summary

The goal of this clinical research study is to learn about the safety and effects of G207 combined with radiation therapy in patients with recurrent or progressive high-grade glioma (HGG).

Primary Outcome

Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0

Interventions

  • DRUG G207

Trial Details

FieldValue
Enrollment Target 38 participants
Start Date 2026-11-30
Est. Completion 2032-12-31
Phase Phase 2
M.D. Anderson Cancer Center

2,692 total trials

What is known before NCT07649070 opens enrollment

NCT07649070 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 38 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (71% lower).

The record links to 0 conditions, and to 1 intervention - of which G207 is the first listed.

NCT07649070 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT07649070 about?

NCT07649070 is a clinical study titled "Phase 2 Trial of G207 + 5 Gy Radiation for Children With High-Grade Gliomas". The goal of this clinical research study is to learn about the safety and effects of G207 combined with radiation therapy in patients with recurrent or progressive high-grade glioma (HGG).

What is the current status of trial NCT07649070?

This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 38 participants. The study started on 2026-11-30. Estimated completion is 2032-12-31.

What interventions are being tested in trial NCT07649070?

The interventions under investigation include: G207 (DRUG).

Who is sponsoring clinical trial NCT07649070?

This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT07649070's enrollment target sits among peer trials

38 1467th of 2000 higher than 517 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01684904 · 38 participants · NA

    Proton Therapy for Esophageal Cancer

  • NCT03310879 · 38 participants · Phase 2

    Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6

  • NCT03896269 · 38 participants · Phase 1

    CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia

  • NCT04085315 · 38 participants · Phase 1

    Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT07649070, the US trial registry maintained by the National Library of Medicine. NCT07649070 (small enrollment · none site footprint · not yet recruiting) retrieved and formatted by PlainTrial, see methodology.